Trial
NCT01560585
Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
University Hospitals Cleveland Medical Center
Collaborators
—
Condition
Alzheimer's Disease
Intervention
Isotretinoin
Why stopped
Adverse events in 2/3 participants; study was halted but not restarted after this due to insufficnet funds as well
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-15